SCHEMBL3858962

SCHEMBL3858962

CCC(C(=O)O)=C(Nc1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ TP53 P04637 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ HPGD P15428 1/20 0.50
▸ GAA P10253 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NAPRT Q6XQN6 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ EPHX1 P07099 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ EPHX2 P34913 1/20 0.44
▸ CDK9 P50750 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ SIRT1 Q96EB6 1/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1273131 0.82 CES1 (0.46) ALDH1A1TP53RAB9AHPGDGAA
SCHEMBL1273132 0.82 CES1 (0.46) ALDH1A1TP53RAB9AHPGDGAA
SCHEMBL10595114 0.79 CES1 (0.43) ALDH1A1RAB9AHPGDGAAMAPT
SCHEMBL10472080 0.79 NAPRT (0.53) ALDH1A1TP53RAB9AHPGDGAA
SCHEMBL11496108 0.79 MAPT (0.51) ALDH1A1TP53RAB9AHPGDGAA
SCHEMBL10472082 0.79 NAPRT (0.53) ALDH1A1TP53RAB9AHPGDGAA
SCHEMBL1273536 0.77 GRM4 (0.51) TP53RAB9AHPGDMAPTSMN1; SMN2
SCHEMBL1273537 0.77 GRM4 (0.51) TP53RAB9AHPGDMAPTSMN1; SMN2
SCHEMBL8022505 0.77 NAPRT (0.55) ALDH1A1TP53RAB9AGAAMAPT
SCHEMBL5329220 0.76 NAPRT (0.50) ALDH1A1TP53RAB9AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687275-A4 PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN MERCK & CO INC (US) 2009-01-14 — — EP disclosed
US-20070099950-A1 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain AGT SCIENCE LIMITED (GB) 2007-05-03 — — US disclosed
EP-1687275-A1 PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN Merck & Co., Inc. (US) 2006-08-09 — — EP disclosed
WO-2005051915-A1 PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN MERCK & CO., INC. (US) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099950-A1 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain PER2, CNR2, OPRD1 ALDH1A1 2085/4885TP53 4828/4885RAB9A 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback